140 related articles for article (PubMed ID: 32488358)
1. Boosting bladder cancer treatment by intravesical nitazoxanide and bacillus calmette-guérin association.
Kiehl IGA; Riccetto E; Salustiano ACC; Ossick MV; Ferrari KL; Assalin HB; Ikari O; Reis LO
World J Urol; 2021 Apr; 39(4):1187-1194. PubMed ID: 32488358
[TBL] [Abstract][Full Text] [Related]
2. Bladder cancer immunomodulatory effects of intravesical Nitazoxanide, Rapamycin, Thalidomide and Bacillus Calmette-Guérin (BCG).
Andrade DL; Jalalizadeh M; Salustiano ACC; Reis LO
World J Urol; 2023 Sep; 41(9):2375-2380. PubMed ID: 37470811
[TBL] [Abstract][Full Text] [Related]
3. Intravesical bacillus Calmette-Guérin efficiently reduces p70S6K1 but not 4E-BP1 phosphorylation in nonmuscle invasive bladder cancer.
Ferrari KL; de Camargo JA; Rocha GZ; Carvalheira JB; Saad MJ; Billis A; Reis LO
J Urol; 2015 Feb; 193(2):682-9. PubMed ID: 25200808
[TBL] [Abstract][Full Text] [Related]
4. Intravesical Immunomodulatory Imiquimod Enhances Bacillus Calmette-Guérin Downregulation of Nonmuscle-invasive Bladder Cancer.
Camargo JA; Passos GR; Ferrari KL; Billis A; Saad MJA; Reis LO
Clin Genitourin Cancer; 2018 Jun; 16(3):e587-e593. PubMed ID: 29174504
[TBL] [Abstract][Full Text] [Related]
5. Histopathologic and molecular comparative analyses of intravesical Aurora kinase-A inhibitor Alisertib with bacillus Calmette-Guérin on precancerous lesions of bladder in a rat model.
Teke K; Yilmaz H; Uslubas AK; Akpinar G; Kasap M; Mutlu O; Yildiz DK; Guzel N; Dillioglugil O
Int Urol Nephrol; 2018 Aug; 50(8):1417-1425. PubMed ID: 29931492
[TBL] [Abstract][Full Text] [Related]
6. Intravesical Thalidomide boosts bacillus Calmette-Guérin (BCG) in non-muscle invasive bladder cancer treatment.
Passos GR; Camargo JA; Ferrari KL; Saad MJA; de Mattos AC; Reis LO
Med Oncol; 2017 Dec; 35(1):3. PubMed ID: 29209984
[TBL] [Abstract][Full Text] [Related]
7. Anti-angiogenic effects of the superantigen staphylococcal enterotoxin B and bacillus Calmette-Guérin immunotherapy for nonmuscle invasive bladder cancer.
Reis LO; Ferreira U; Billis A; Cagnon VH; Fávaro WJ
J Urol; 2012 Feb; 187(2):438-45. PubMed ID: 22177150
[TBL] [Abstract][Full Text] [Related]
8. Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Non-muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-Guérin.
Li R; Sundi D; Zhang J; Kim Y; Sylvester RJ; Spiess PE; Poch MA; Sexton WJ; Black PC; McKiernan JM; Steinberg GD; Kamat AM; Gilbert SM
Eur Urol; 2020 Sep; 78(3):387-399. PubMed ID: 32143924
[TBL] [Abstract][Full Text] [Related]
9. Non-maintenance intravesical Bacillus Calmette-Guérin induction therapy with eight doses in patients with high- or highest-risk non-muscle invasive bladder cancer: a retrospective non-randomized comparative study.
Miyake M; Iida K; Nishimura N; Miyamoto T; Fujimoto K; Tomida R; Matsumoto K; Numakura K; Inokuchi J; Morizane S; Yoneyama T; Matsumura Y; Abe T; Inoue M; Yamada T; Terada N; Hirao S; Uemura M; Matsushita Y; Taoka R; Kobayashi T; Kojima T; Matsui Y; Kitamura H; Nishiyama H;
BMC Cancer; 2021 Mar; 21(1):266. PubMed ID: 33706705
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of intensive instillation of low-dose pirarubicin vs. bacillus Calmette-Guérin in patients with high-risk non-muscle-invasive bladder cancer.
Fujita N; Hatakeyama S; Momota M; Kido K; Narita T; Tobisawa Y; Yoneyama T; Yamamoto H; Imai A; Ito H; Yoneyama T; Hashimoto Y; Yoshikawa K; Ohyama C
Urol Oncol; 2020 Aug; 38(8):684.e17-684.e24. PubMed ID: 32278732
[TBL] [Abstract][Full Text] [Related]
11. Intravesical Bacillus Calmette-Guérin with interferon-alpha versus intravesical Bacillus Calmette-Guérin for treating non-muscle-invasive bladder cancer.
Shepherd AR; Shepherd E; Brook NR
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012112. PubMed ID: 28268259
[TBL] [Abstract][Full Text] [Related]
12. Intravesical Bacillus Calmette-Guérin Versus Combination of Epirubicin and Interferon-α2a in Reducing Recurrence of Non-Muscle-invasive Bladder Carcinoma: FinnBladder-6 Study.
Marttila T; Järvinen R; Liukkonen T; Rintala E; Boström P; Seppänen M; Tammela T; Hellström P; Aaltomaa S; Leskinen M; Raitanen M; Kaasinen E;
Eur Urol; 2016 Aug; 70(2):341-7. PubMed ID: 27085624
[TBL] [Abstract][Full Text] [Related]
13. Bacillus Calmette-Guérin with or without interferon α-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer.
Nepple KG; Lightfoot AJ; Rosevear HM; O'Donnell MA; Lamm DL;
J Urol; 2010 Nov; 184(5):1915-9. PubMed ID: 20846688
[TBL] [Abstract][Full Text] [Related]
14. Maintenance intravesical bacillus Calmette-Guérin instillation for Ta, T1 cancer and carcinoma in situ of the bladder: randomized controlled trial by the BCG Tokyo Strain Study Group.
Koga H; Ozono S; Tsushima T; Tomita K; Horiguchi Y; Usami M; Hirao Y; Akaza H; Naito S;
Int J Urol; 2010 Sep; 17(9):759-66. PubMed ID: 20604814
[TBL] [Abstract][Full Text] [Related]
15. A prospective comparative study to assess the efficacy and tolerability of 2 different doses of intravesical bacillus Calmette-Guerin (BCG) in patients with non-muscle-invasive bladder cancer.
Sood R; Sharma H; Sharma B; Parekh S; Pujari P; Shewale S
Urol Oncol; 2020 May; 38(5):433-439. PubMed ID: 32037199
[TBL] [Abstract][Full Text] [Related]
16. The effect of intravesical instillation of antifibrinolytic agents on bacillus Calmette-Guerin treatment of superficial bladder cancer: a pilot study.
Pan CW; Shen ZJ; Ding GQ
J Urol; 2008 Apr; 179(4):1307-11; discussion 1311-2. PubMed ID: 18289576
[TBL] [Abstract][Full Text] [Related]
17. Determining optimal maintenance schedules for adjuvant intravesical bacillus Calmette-Guerin immunotherapy in non-muscle-invasive bladder cancer: a systematic review and network meta-analysis.
Huang Z; Liu H; Wang Y; Zhang C; Xu T
Curr Med Res Opin; 2017 Aug; 33(8):1379-1387. PubMed ID: 28471272
[TBL] [Abstract][Full Text] [Related]
18. Can we treat bladder cancer with intravesical Bacillus Calmette-Guerin in patients with prior tuberculosis infection? A population-based cohort study.
Hsu CW; Chiu YC; Hu HY; Fan YH; Hong SC; Cheng WM
BMC Urol; 2020 Jul; 20(1):91. PubMed ID: 32641099
[TBL] [Abstract][Full Text] [Related]
19. Intravesical Bacillus Calmette-Guérin versus epirubicin for Ta and T1 bladder cancer.
Shang PF; Kwong J; Wang ZP; Tian J; Jiang L; Yang K; Yue ZJ; Tian JQ
Cochrane Database Syst Rev; 2011 May; (5):CD006885. PubMed ID: 21563157
[TBL] [Abstract][Full Text] [Related]
20. Carcinogenesis and Bacillus Calmette-Guérin (BCG) Intravesical Treatment of Non-Muscle-Invasive Bladder Cancer under Tryptophan and Thymine Supplementation.
Ossick MV; Assalin HB; Kiehl IGA; Salustiano ACC; Rocha GZ; Ferrari KL; Linarelli MCB; Degasperi G; Reis LO
Nutr Cancer; 2021; 73(11-12):2687-2694. PubMed ID: 33287590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
